Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., listed under the ticker LACQ, is a clinical-stage pharmaceutical company focused on developing abuse-deterrent formulations for opioid and stimulant therapeutics. The company reached the public markets through a special purpose acquisition company vehicle that completed its initial public offering in 2020, placing Ensysce within the healthcare and life sciences sector. A Form 10-Q was filed with the SEC on June 8, 2021, under accession number 0001493152-21-013768, reflecting the company's quarterly reporting obligations following its SPAC-related transaction activity. The filing is currently indexed and available through the SEC's EDGAR system. To access full deal documents, sponsor profiles, timeline data, and ongoing SPAC analytics for LACQ and hundreds of other vehicles, sign up for SpacDesk at spacdesk.com.